BURLINGTON, Mass. – May 1, 2014 – inVentiv Health, a life science knowledge and services company, announced today that five talented women executives have been selected as 2014 “Rising Stars” by the Healthcare Businesswomen’s Association (HBA). The honorees were recognized at the 25th annual HBA Woman of the Year award luncheon, held today in New York City, New York.
Each year, the HBA recognizes women from across the nation in the healthcare industry who exhibit visionary leadership skills, are solely dedicated to the healthcare industry, and contribute significantly to their organizations. To qualify as Rising Stars, honorees must also promote growth opportunities for others and serve as role models within their respective companies. All the inVentiv Health honorees are exemplary Rising Stars.
To celebrate the 25th anniversary of the awards, HBA created a first-ever “Luminary” category, acknowledging 25 previous Rising Stars who have continued to make a significant impact on the healthcare industry. Luminary award winners also must have experienced rapid career advancement since receiving their initial award.
Chandler Chicco Companies President, Lisa Stockman, was honored as one of the 25 HBA Luminaries. Stockman was named an HBA Rising Star in 2005. This year’s Rising Stars at inVentiv Health include Meg Alexander of Chandler Chicco Companies, Jemma Contreras of Campbell Alliance, Jeannine Doumar of GSW, and Julie Priddle of Palio+Ignite.
“These Rising Stars represent some of the most remarkable talent in healthcare. Each of these women is a respected expert in helping clients develop and commercialize drugs that improve patient outcomes worldwide,” said Mike Griffith, Executive Vice President. “On behalf of inVentiv Health, I want to congratulate each of these distinguished women on this well-deserved honor.”
The combined experience of inVentiv’s five honorees spans several decades and a variety of healthcare-specific disciplines, including consulting, advertising and public relations:
“Together, these five honorees are helping inVentiv Health redefine services for the biopharmaceutical industry,” Griffith said. “We are proud of their achievement.”
About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client’s development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit http://www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.